2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT

British Journal of Cancer

Volumn 90, Issue 5, 2004, Pages 1084-1092

  Helsby, N A ^a   Ferry, D M ^a   Patterson, A V ^a   Pullen, S M ^a   Wilson, W R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bystander effect; CB 1954; GDEPT; Nitroreductase; Prodrugs; SN 23862

Indexed keywords

2 HYDROXYLAMINE; 4 HYDROXYLAMINE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; AMINE; CHLORMETHINE DERIVATIVE; DNA; DRUG METABOLITE; NITROREDUCTASE; SN 23862; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL REGENERATION; CONTROLLED STUDY; CYTOTOXICITY; DIFFUSION; DNA CROSS LINKING; DNA REPAIR; DRUG DIFFUSION; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; MEDIATOR; PRIORITY JOURNAL; TUMOR CELL CULTURE; UTERINE CERVIX CARCINOMA;

ANILINE MUSTARD; ANTINEOPLASTIC AGENTS; AZIRIDINES; BYSTANDER EFFECT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ESCHERICHIA COLI; GENE THERAPY; GENETIC VECTORS; HUMANS; MASS SPECTROMETRY; NEOPLASMS; NITROREDUCTASES; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 1942424798     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601612     Document Type: Article

References (36)

1. Anlezark GM, Melton RG, Sherwood RF, Coles B, Friedlos F, Knox RJ (1992) The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) - I. Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 44: 2289-2295
2. Anlezark GM, Melton RG, Sherwood RF, Wilson WR, Denny WA, Palmer BD, Knox RJ, Friedlos F, Williams A (1995) Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem Pharmacol 50: 609-618
3. Anlezark GM, Vaughan T, Fashola-Stone E, Michael NP, Murdoch H, Sims MA, Stubbs S, Wigley S, Minton NP (2002) Bacillus amyloliquefaciens orthologue of Bacillus subtilis ywrO encodes a nitroreductase enzyme which activates the prodrug CB 1954. Microbiology 148: 297-306
4. Boland MP, Knox RJ, Roberts JJ (1991) The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem Pharmacol 41: 867-875
5. Bridgewater JA, Knox RJ, Pitts JD, Collins MK, Springer CJ (1997) The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum Gene Ther 8: 709-717
6. Chung-Faye G, Palmer D, Anderson D, Clark J, Downes M, Baddeley J, Hussain S, Murray PI, Searle P, Seymour L, Harris PA, Ferry D, Kerr DJ (2001) Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res 7: 2662-2668
7. Djeha AH, Hulme A, Dexter MT, Mountain A, Young LS, Searle PF, Kerr DJ, Wrighton CJ (2000) Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther 7: 721-731
8. Friedlos F, Court S, Ford M, Denny WA, Springer C (1998) Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Therapy 5: 105-112
9. Friedlos F, Denny WA, Palmer BD, Springer CJ (1997) Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. J Med Chem 40: 1270-1275
10. Green NK, Youngs DJ, Neoptolemos JP, Friedlos F, Knox RJ, Springer CJ, Anlezark GM, Michael NP, Melton RG, Ford MJ, Young LS, Kerr DJ, Searle PF (1997) Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther 4: 229-238
11. Hansch C, Leo A (1979) Substituent Constants for Correlation Analysis in Chemistry and Biology. New York: John Wiley & Sons
12. Helsby NA, Wheeler SJ, Pruijn FB, Palmer BD, Yang S, Denny WA, Wilson WR (2003) Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. Chem Res Toxicol 16: 469-478
13. Hicks KO, Pruijn FB, Baguley BC, Wilson WR (2001) Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(dimethylamino)ethyl] acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells. J Pharmacol Exp Ther 297: 1088-1098
14. Hicks KO, Pruijn FB, Sturman JR, Denny WA, Wilson WR (2003) Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layers. Cancer Res 63: 5970-5977
15. Hobbs S, Jitrapakdee S, Wallace JC (1998) Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun 252: 368-372
16. Hoy CA, Thompson LH, Mooney CL, Salazar EP (1985) Defective DNA cross-link removal in Chinese hamster cell mutants hypersensitive to bifunctional alkylating agents. Cancer Res 45: 1737-1743
17. Jarman M, Melzack DH, Ross WCJ (1976) The metabolism of the anti-tumour agent 5-(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954). Biochem Pharmacol 25: 2475-2478
18. Kestell P, Pruijn FB, Siim BG, Palmer BD, Wilson WR (2000) Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (SN 23862) and the corresponding aziridine (CB 1954) in KHT tumour-bearing mice. Cancer Chemother Pharmacol 46: 365-374
19. Knox RJ, Boland MP, Friedlos F, Coles B, Southan C, Roberts JJ (1988a) The nitroreductase enzyme in walker cells that activates 5-(aziridin-1-yl)-2,4- dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2- nitrobenzamide, is a form of NAD(P)H dehydrogenase (quinone) (EC1.6.99.2). Biochem Pharmacol 37: 4671-4677
20. Knox RJ, Friedlos F, Biggs PJ, Flitter WD, Gaskell M, Goddard P, Davies L, Jarman M (1993) Identification, synthesis and properties of 5-(aziridin-1-yl)2-nitro-4-nitrosobenzamide, a novel DNA crosslinking agent derived from CB1954. Biochem Pharmacol 46: 797-803
21. Knox RJ, Friedlos F, Jarman M, Roberts JJ (1988b) A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2- nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem Pharmacol 37: 4661-4669
22. Knox RJ, Friedlos F, Marchbank T, Roberts JJ (1991) Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem Pharmacol 42: 1691-1697
23. Knox RJ, Friedlos F, Sherwood RF, Melton RG, Anlezark GM (1992) The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) - II. A comparison of an Eschericia coli nitroreductase and Walker DT diaphorase. Biochem Pharmacol 44: 2297-2301
24. Lemmon MJ, van Zijl P, Fox ME, Mauchline ML, Giaccia AJ, Minton NP, Brown JM (1997) Anaerobic bacteria as a gene delivery system that is controlled by the tumour microenvironment. Gene Therapy 4: 791-796
25. McNeish IA, Green NK, Gilligan MG, Ford MJ, Mautner V, Young LS, Kerr DJ, Searle PF (1998) Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Therapy 5: 1061-1069
26. Nishihara E, Nagayama Y, Narimatsu M, Namba H, Watanabe M, Niwa M, Yamashita S (1998) Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations {In Vitro}. Anticancer Res 18: 1521-1526
27. Palmer BD, van Zijl P, Denny WA, Wilson WR (1995) Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4- dinitrobenzamide. J Med Chem 38: 1229-1241
28. Palmer BD, Wilson WR, Cliffe S, Denny WA (1992) Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. J Med Chem 35: 3214-3222
29. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112
30. Sunters A, Springer CJ, Bagshawe KD, Souhami RL, Hartley JA (1992) The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[bis(2-chloroethyl)amino] benzoic acid. Biochem Pharmacol 44: 59-64
31. Walton MI, Wolf CR, Workman P (1989) Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys 16: 983-986
32. Westphal EM, Ge J, Catchpole JR, Ford M, Kenney SC (2000) The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: induction of bystander killing in vitro and in vivo. Cancer Gene Ther 7: 97-106
33. Wilson WR, Denny WA, Pullen SM, Thompson KM, Li AE, Patterson LH, Lee HH (1996) Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. Br J Cancer Suppl 27: S43-S47
34. Wilson WR, Pullen SM, Hogg A, Helsby NA, Hicks KO, Denny WA (2002) Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res 62: 1425-1432
35. Wilson WR, Pullen SM, Hogg A, Hobbs SM, Pruijn FB, Hicks KO (2003) In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumors. In Suicide Gene Therapy: Methods and Reviews, Springer CJ (ed) pp 403-432. Totowa: Humana Press
36. Young JG, Leung HY, Searle PF, Mautner V, Howie A, Horne M, Ellis J, Gilbert J, Neal DE, Harris P, Doherty AP, Wallace DMA, James ND (2002) Direct injection of adenovirus for enzyme prodrug therapy of prostate cancer. Br J Cancer 86: s30